MSB

8.42%

$1.03 mesoblast limited

Ann: Annual Financial Results Presentation, page-84

First 84 Last

Share
Profile

Follow
FreddieF

49 Posts.

18

27/08/20

19:50

Post #: 46878447
Share

Originally posted by dontfollowme: ↑

Increasing short positions have been in both market's since the big ODAC push down and bounce back up. Seems the churn is around 15% of daily volume on ASX. ASIC reported shorts were 1.3 million for 26th August and there was an instant drop on open when most may have been traded. If there are still 34 million short sold that's around 7 days to cover on current daily volumes. US market I'm not to sure why the increase as well....but someones taking a punt.
I don't think its a case of blink and miss because I still have a gut feeling there will be another push down...how that is executed?
Could be wrong footing the market interpretation of results or decision, but thats only a slim one.
Could be a massive sellside flood to drive things south, sustained by the team on both markets.
If there is any negative press out there then that will become a weapon.
Also a damning broker report from those in the game may help to turn tides.
All these things can occur especially when the market is skittish and fickle.
I think we will see more opportunity ahead to add/buy/trade, so no hast required. There's never anything wrong with adding on the way up, better than on the way down most times. Conservative pricing of MSB may fall by the wayside if all goes in the companies favour these coming months but looking at the chart expect peaks and troughs, these may get more pronounced or could take longer to change direction.
Thinking BNPL stocks look at the upside and holders adding everytime the stock rises 20% are doing fine, sure the shares are getting expensive but your avg stays low and your investment compounds, I see the potential for MSB to do the same, to what extent, well that's anyone's educated guess. If I was too hazard a guess I'm thinking $15 on ARDS and FDA approval for Ryoncil and emergency use for Covid with ongoing treatment trial. If no FDA approval for Ryoncil and ARDS trial shows poor efficacy then back to $2. Potential in next 12 months? $30 although biotech roller coasters have a habit of overshooting........All imo. Hold fast.

Expand

Thanks @dontfollowme. I agree with everything here, but in particular I wanted to reiterate that the there is nothing wrong with averaging up.

My mate’s old man (RIP) was a board member of a prominent broker house and I remember his take on this:

‘Averaging down killed more people than the plague’.

Buy and buy again if the fundamentals say you should. Yes, scoop up some more when the price is driven down, but if you think MSB could be a $50 stock in five years...........then $5.20, $6.00, $10.00......well these are bargains. I’m accumulating as I can.

No advice is intended.

MSB Price at posting: $5.20 Sentiment: Buy Disclosure: Held
47 Upvote

1 Great analysis

Reply

Top Stories

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

CCO

The Calmer Co’s Anthony Noble reflects on record breaking FY24

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

HLX

Helix investor makes partial takeover bid, proposing board changes

There are more pages in this discussion • 14 more messages in this thread...

First 84 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.03		Change 0.080(8.42%)		Mkt cap ! $1.176B

Open	High	Low	Value	Volume
95.5¢	$1.03	95.0¢	$43.38M	42.28M

Buyers (Bids)

No.	Vol.	Price($)
4	72752	$1.01

Sellers (Offers)

Price($)	Vol.	No.
$1.03	205100	2

View Market Depth

No.	Vol.	Price($)
1	20000	1.005
5	57985	1.000
1	50000	0.995
2	20525	0.990
1	10000	0.985

Price($)	Vol.	No.
1.035	190122	7
1.045	39714	5
1.050	21696	6
1.060	9750	2
1.065	5780	1

Last trade - 16.10pm 30/08/2024 (20 minute delay)

MSB (ASX) Chart

Ann: Annual Financial Results Presentation, page-84

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

The Calmer Co’s Anthony Noble reflects on record breaking FY24

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Lendlease sells off US east coast construction operations in latest global divestment push

Helix investor makes partial takeover bid, proposing board changes

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Annual Financial Results Presentation, page-84

Top Stories

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

The Calmer Co’s Anthony Noble reflects on record breaking FY24

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Lendlease sells off US east coast construction operations in latest global divestment push

Helix investor makes partial takeover bid, proposing board changes

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News